DANIEL PERLOW

CLEVELAND, OH NPI 1508568320

General Payments — all program years on this page

$352.52

  • Category: General Payments
  • Program years: PY2024
  • Record count: 20
  • As of (CMS publication): 2026-01-23

Latest program year (PY2024): $352.52 across 20 records · disputed records: 0

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How this figure is calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

Latest program year (PY2024) · sorted by reported total.

Nature of paymentAmountRecords
Food and Beverage $352.5220

By paying entity

Latest program year (PY2024) · sorted by reported total.

Paying entityAmountRecords
UCB, Inc. $103.145
JAZZ PHARMACEUTICALS INC. $82.504
Acerta Pharma LLC $63.294
NOVARTIS PHARMACEUTICALS CORPORATION $62.674
PFIZER INC. $27.832
TG THERAPEUTICS, INC. $13.091

By program year

Program yearAmountRecords
2024 $352.5220

Records — PY2024 (20)

Record IDPaying entityAmountDate Nature of paymentDispute statusPublishedSource
1087309301 Novartis Pharmaceuticals Corporation $14.97 04/03/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1087309303 Novartis Pharmaceuticals Corporation $14.15 05/07/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1087309307 Novartis Pharmaceuticals Corporation $15.69 07/30/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1087309313 Novartis Pharmaceuticals Corporation $17.86 10/11/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1110509774 AstraZeneca Pharmaceuticals LP $14.72 03/06/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1110509990 AstraZeneca Pharmaceuticals LP $19.16 09/05/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1110513574 AstraZeneca Pharmaceuticals LP $14.69 04/10/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1110515432 AstraZeneca Pharmaceuticals LP $14.72 08/28/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1131792731 PFIZER INC. $13.33 07/23/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1131899807 PFIZER INC. $14.50 08/16/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1136880746 TG Therapeutics, Inc. $13.09 08/29/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1143508896 UCB, Inc. $23.46 03/20/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1143508902 UCB, Inc. $20.81 08/14/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1143508907 UCB, Inc. $19.39 08/19/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1143508912 UCB, Inc. $16.63 08/29/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1143508917 UCB, Inc. $22.85 12/09/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1150218497 JAZZ PHARMACEUTICALS INC. $17.67 06/06/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1150218499 JAZZ PHARMACEUTICALS INC. $18.97 03/06/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1150218501 JAZZ PHARMACEUTICALS INC. $16.53 07/18/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1150218503 JAZZ PHARMACEUTICALS INC. $29.33 10/30/2024 Food and Beverage Undisputed 01/23/2026 View at CMS

Provenance & corrections

  • Dataset: CMS Open Payments — General Payments
  • Source: CMS Open Payments dataset (bulk file)
  • Publisher of source data: Centers for Medicare & Medicaid Services
  • Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.